REGN - Regeneron Pharmaceuticals, Inc.
| Previous close | 452.30 |
| Open | 446.03 |
| Bid | 451.01 x 900 |
| Ask | 455.00 x 900 |
| Day's range | 445.15 - 465.79 |
| 52-week range | 271.37 - 518.00 |
| Volume | 1,109,194 |
| Avg. volume | 1,238,609 |
| Market cap | 49.456B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 24.35 |
| EPS (TTM) | 18.46 |
| Earnings date | 04 May 2020 - 10 May 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 475.00 |
- Zacks
Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
- Zacks
Biotech Stocks Accelerate Efforts for Coronavirus Treatments
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
- Zacks
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
- Zacks
Top 5 Drug Stocks To Stop The Coronavirus Pandemic
It is only a matter of time before this virus anxiety is a thing of the past.
- Zacks
Coronavirus Drug Development Race to Boost These 4 Stocks
Fast-track approval for coronavirus drug trials is encouraging drug developers. Here are four stocks that can make the most of this phase.
- Zacks
US Government Reaches Deal on Stimulus Package: 5 Top Picks
The U.S. government and Senate reached an agreement to inject $2 trillion of stimulus to boost the U.S. economy amid the coronavirus-induced turmoil.
- Zacks
Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Regeneron (REGN) closed at $449.53, marking a -1.34% move from the previous day.
- Zacks
Top Ranked Momentum Stocks to Buy for March 24th
Top Ranked Momentum Stocks to Buy for March 24th
- Zacks
The Zacks Analyst Blog Highlights: Calix, CBIZ, The Ensign Group, Regeneron Pharmaceuticals and Turning Point Brands
The Zacks Analyst Blog Highlights: Calix, CBIZ, The Ensign Group, Regeneron Pharmaceuticals and Turning Point Brands
- Zacks
Market is Wavering! Buy 5 Best Low-Volatility Stocks Now
Low-volatility stocks tend to hold up better in tough times. More interestingly, these stocks have done better over longer periods of time, even before the coronavirus-induced market crash.
- Zacks
Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates
Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.
- Zacks
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
The Zacks Analyst Blog Highlights: Moderna, Novavax and Regeneron Pharmaceuticals
- Zacks
Roche to Evaluate Actemra for Severe COVID-19 Pneumonia
Roche (RHHBY) works with the FDA to evaluate the safety and efficacy of rheumatoid arthritis drug, Actemra, in severe COVID-19.
- Zacks
5 Low-Beta Stocks to Tackle Coronavirus-Led Market Volatility
The current volatility in equity market calls for investment in these five low-beta stocks.
- Zacks
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
- Zacks
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
- Zacks
Regeneron (REGN) Stock Moves -1.36%: What You Should Know
Regeneron (REGN) closed the most recent trading day at $485, moving -1.36% from the previous trading session.
- Zacks
Merck's Chronic Cough Candidate Achieves Goals in Phase III
Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.
- Zacks
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
- Zacks
Pfizer, Regeneron Give Update on Coronavirus Drug Development
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
- Zacks
Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys
Shares of Moderna soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19
- Zacks
Regeneron Up on Identification of Antibodies for Coronavirus
Regeneron (REGN) announces identification of antibodies from its VelocImmune mice for the treatment of coronavirus.
- Zacks
5 Stocks in the S&P 500 ETF Still Up YTD
Though most stocks in the S&P 500 ETF portfolio are in red from the year-to-date look, there are a few that are standing tall in the ongoing market turmoil.
- Zacks
Why Regeneron (REGN) Stock Might be a Great Pick
Regeneron (REGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
